ITGAM and neoplasm: Previous studies have indicated that CD44 on tumor cells and CD11b on T cells can act as ligands for siglec-15, suggesting that siglec-15 may interact with different ligands from various cell types, further influencing its role in tumor progression and immune regulation [37,38].